UniProt Q8TEK3
Histone-lysine N-methyltransferase, H3 lysine-79 specific (Q8TEK3)
Histone-lysine N-methyltransferase, H3 lysine-79 specific (UniProt Q8TEK3), EC 2.1.1.43: 72 experimental structures and 1 predicted model on GenesisL1, 16 ligands bound, 14 pockets. Binding sites, druggability and experiment…
- UniProt
- Q8TEK3
- Protein
- Histone-lysine N-methyltransferase, H3 lysine-79 specific
- EC
- 2.1.1.43
- Experimental structures
- 72
- Predicted models
- 1
- Ligands
- 16
- Pockets
- 14 · 3 records with a druggable one
Structures
73 records of Q8TEK3 in the MolNFT archive: 72 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1NW3 | Structure of the Catalytic domain of human DOT1L, a non-SET domain nucleosomal histone… | x-ray diffraction | A | — | — |
| 1NW3 | Structure of the catalytic domain of human DOT1L, a non-set domain nucleosomal histone… | x-ray diffraction | A | — | — |
| 2MV7 | Solution NMR structure of DOT1L in complex with AF9 (DOT1L-AF9) | solution nmr | B | — | — |
| 2MV7 | Solution NMR structure of DOT1L in complex with AF9 (DOT1L-AF9) | solution nmr | B | — | — |
| 3QOW | DOT1L Structure in complex with SAM | x-ray diffraction | A | — | — |
| 3QOW | DOT1L structure in complex with SAM | x-ray diffraction | A | — | — |
| 3QOX | DOT1L structure in complex with SAH | x-ray diffraction | A | — | — |
| 3QOX | DOT1L structure in complex with sah | x-ray diffraction | A | — | — |
| 3SR4 | Crystal Structure of Human DOT1L in Complex with a Selective Inhibitor | x-ray diffraction | A | — | — |
| 3SR4 | Crystal structure of human DOT1L in complex with a selective inhibitor | x-ray diffraction | A | — | — |
| 3SX0 | Crystal structure of Dot1l in complex with a brominated SAH analog | x-ray diffraction | A | — | — |
| 3SX0 | Crystal structure of DOT1L in complex with a brominated sah analog | x-ray diffraction | A | — | — |
| 3UWP | Crystal structure of Dot1l in complex with 5-iodotubercidin | x-ray diffraction | A | — | — |
| 3UWP | Crystal structure of DOT1L in complex with 5-iodotubercidin | x-ray diffraction | A | — | — |
| 4EK9 | Crystal structure of DOT1L in complex with EPZ000004 | x-ray diffraction | A | — | — |
| 4EK9 | Crystal structure of DOT1L in complex with EPZ000004 | x-ray diffraction | A | — | — |
| 4EKG | Crystal Structure of DOT1L in Complex with EPZ003696 | x-ray diffraction | A | — | — |
| 4EKG | Crystal structure of DOT1L in complex with EPZ003696 | x-ray diffraction | A | — | — |
| 4EKI | Crystal Structure of DOT1L in complex with EPZ004777 | x-ray diffraction | A | — | — |
| 4EKI | Crystal structure of DOT1L in complex with EPZ004777 | x-ray diffraction | A | — | — |
| 4EQZ | Crystal structure of human DOT1L in complex with inhibitor FED2 | x-ray diffraction | A | — | — |
| 4EQZ | Crystal structure of human DOT1L in complex with inhibitor FED2 | x-ray diffraction | A | — | — |
| 4ER0 | Crystal Structure of human DOT1L in complex with inhibitor FED1 | x-ray diffraction | A | — | — |
| 4ER0 | Crystal structure of human DOT1L in complex with inhibitor FED1 | x-ray diffraction | A | — | — |
| 4ER3 | Crystal Structure of Human DOT1L in complex with inhibitor EPZ004777 | x-ray diffraction | A | — | — |
| 4ER3 | Crystal structure of human DOT1L in complex with inhibitor EPZ004777 | x-ray diffraction | A | — | — |
| 4ER5 | Crystal structure of human DOT1L in complex with 2 molecules of EPZ004777 | x-ray diffraction | A | — | — |
| 4ER5 | Crystal structure of human DOT1L in complex with 2 molecules of EPZ004777 | x-ray diffraction | A | — | — |
| 4ER6 | Crystal structure of human DOT1L in complex with inhibitor SGC0946 | x-ray diffraction | A | — | — |
| 4ER6 | Crystal structure of human DOT1L in complex with inhibitor SGC0946 | x-ray diffraction | A | — | — |
| 4ER7 | Crystal Structure of human DOT1L in complex with inhibitor SGC0947 | x-ray diffraction | A | — | — |
| 4ER7 | Crystal structure of human DOT1L in complex with inhibitor SGC0947 | x-ray diffraction | A | — | — |
| 4HRA | Crystal Structure of DOT1L in Complex with EPZ-5676 | x-ray diffraction | A | — | — |
| 4HRA | Crystal structure of DOT1L in complex with epz-5676 | x-ray diffraction | A | — | — |
| 4WVL | Structure-guided DOT1L probe optimization by label-free ligand displacement | x-ray diffraction | A | — | — |
| 5DRT | Crystal structure of Dot1L in complex with inhibitor CPD2… | x-ray diffraction | A, B | 5EG, K | — |
| 5DRT | Crystal structure of DOT1L in complex with inhibitor CPD2 [2-(2-(5… | x-ray diffraction | A, B | — | — |
| 5DRY | Crystal structure of Dot1L in complex with inhibitor CPD3… | x-ray diffraction | A, B | K, 5EK | — |
| 5DRY | Crystal structure of DOT1L in complex with inhibitor CPD3 [N-(1-(2… | x-ray diffraction | A, B | — | — |
| 5DSX | Crystal structure of DOT1L in complex with inhibitor CPD10 [6'-chloro… | x-ray diffraction | A, B | — | — |
| 5DT2 | Crystal structure of Dot1L in complex with inhibitor CPD11… | x-ray diffraction | A, B | 5EV, SO4 | — |
| 5DT2 | Crystal structure of DOT1L in complex with inhibitor CPD11 [N4-methyl… | x-ray diffraction | A, B | — | — |
| 5DTM | Crystal structure of Dot1L in complex with inhibitor CPD1… | x-ray diffraction | A, B | 5F4 | — |
| 5DTM | Crystal structure of DOT1L in complex with inhibitor CPD1 [4-(2,6… | x-ray diffraction | A, B | — | — |
| 5DTQ | Crystal structure of DOT1L in complex with inhibitor CPD3 [(2,6… | x-ray diffraction | A, B | — | — |
| 5DTR | Crystal structure of DOT1L in complex with inhibitor CPD5 [N-(2,6… | x-ray diffraction | A, B | — | — |
| 5JUW | Complex of DOT1L with SS148 | x-ray diffraction | A | — | — |
| 5MVS | Crystal structure of DOT1L in complex with adenosine and inhibitor CPD1… | x-ray diffraction | A, B | ADN, 5JJ | — |
| 5MW3 | Crystal structure of DOT1L in complex with inhibitor CPD1 [N6-(2,6… | x-ray diffraction | A, B | 5JJ, 5JT | — |
| 5MW4 | Crystal structure of Dot1L in complex with inhibitor CPD7… | x-ray diffraction | A, B | 5JU, SO4 | — |
| 5MW4 | Crystal structure of DOT1L in complex with inhibitor CPD7 [N-(3-(((R)… | x-ray diffraction | A, B | 5JU, SO4 | — |
| 6IN3 | Crystal structure of DOT1L in complex with 18-crown-6 | x-ray diffraction | A | O4B, SO4 | — |
| 6J99 | Cryo-EM structure of human DOT1L in complex with an H2B-monoubiquitinated nucleosome | electron microscopy | K | SAH | 4 (best 0.85) |
| 6J99 | Cryo-EM structure of human DOT1L in complex with an H2B- monoubiquitinated nucleosome | electron microscopy | K | — | — |
| 6JM9 | cryo-EM structure of DOT1L bound to unmodified nucleosome | electron microscopy | X | SAM | 2 (best 0.73) |
| 6JM9 | Cryo-EM structure of DOT1L bound to unmodified nucleosome | electron microscopy | X | — | — |
| 6JMA | Cryo-EM structure of DOT1L bound to H2B ubiquitinated nucleosome | electron microscopy | X | — | — |
| 6JN2 | Crystal structure of the coiled-coil domains of human DOT1L in complex with AF10 | x-ray diffraction | B | — | — |
| 6JN2 | Crystal structure of the coiled-coil domains of human DOT1L in complex with AF10 | x-ray diffraction | B | — | — |
| 6NJ9 | Active state DOT1L bound to the H2B-ubiquitinated nucleosome, 2-to-1 complex | electron microscopy | K, M | — | — |
13 records more on the page itself.
Ligands
- SO4 · Sulfate ion · in 5 records
- K · Potassium ion · in 3 records
- 5JJ · N~6~-(2,6-dichlorophenyl)-N~6~-(pent-2-yn-1-yl) quinoline-4,6-diamine · in 2 records
- 5JU · N~2~-{[2-chloro-3-(2-methylpyridin-3-yl)-1-benzothiophen-5-yl]carbamoyl}-N-(3-{methyl[(3R)-1-(5H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl]amino}propyl)glycinamide · in 2 records
- SAM · S-adenosylmethionine · in 2 records
- 5EG · 2-({5-[(2-chlorophenoxy)methyl]-1H-tetrazol-1-yl}acetyl)-N-(4-chlorophenyl)hydrazinecarboxamide · in 1 record
- 5EK · N-[1-(2-chlorophenyl)-1H-indol-6-yl]-2-{[5-(2-chlorophenyl)-1H-tetrazol-1-yl]acetyl}hydrazinecarboxamide · in 1 record
- 5EV · N~4~-methyl-N~2~-[2-methyl-1-(2-phenoxyphenyl)-1H-indol-6-yl]pyrimidine-2,4-diamine · in 1 record
- 5F4 · 4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide · in 1 record
- 5JT · (3R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine · in 1 record
- ADN · Adenosine · in 1 record
- N4W · ~{N}1-[(~{S})-(3-chlorophenyl)-pyridin-2-yl-methyl]-4-methylsulfonyl-~{N}2-pyrimidin-2-yl-benzene-1,2-diamine · in 1 record
- N4Z · ~{N}1-[(~{S})-[2,2-bis(fluoranyl)-1,3-benzodioxol-4-yl]-(3-chloranylpyridin-2-yl)methyl]-~{N}2-(4-methoxy-6-piperazin-1-yl-1,3,5-triazin-2-yl)-4-methylsulfonyl-benzene-1,2-diamine · in 1 record
- N5K · 3-[(4-azanyl-6-methoxy-1,3,5-triazin-2-yl)amino]-4-[[(~{S})-[2,2-bis(fluoranyl)-1,3-benzodioxol-4-yl]-(3-chloranylpyridin-2-yl)methyl]amino]benzenesulfonamide · in 1 record
- O4B · 1,4,7,10,13,16-hexaoxacyclooctadecane · in 1 record
- SAH · S-adenosyl-L-homocysteine · in 1 record
Experiment against prediction
- 6IN3 chain A against the predicted model Q8TEK3: TM-score 0.99, RMSD 0.58 Å
- 3QOW chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.21 Å
- 3QOW chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.21 Å
- 4EK9 chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.21 Å
- 4EK9 chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.21 Å
- 3QOX chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.18 Å
- 3QOX chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.18 Å
- 4ER0 chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.15 Å
- 4ER0 chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.15 Å
- 5JUW chain A against the predicted model Q8TEK3: TM-score 0.98, RMSD 1.19 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.